Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02223208

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (FIL_PTCL13)

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Sponsor: Fondazione Italiana Linfomi - ETS

Conditions ALK- Anaplastic Large Cell Lymphoma (ALCL) Angioimmunoblastic T-cell Lymphoma (AITL) Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin PTCL-NOS Peripheral T-cell Lymphomas (PTCL)

Interventions Ro-CHOEP-21 (PHASE I) Ro-CHOEP-21 (PHASE II)

Updated 23 times since 2017 Last updated: Dec 1, 2025 Started: Sep 30, 2014 Primary completion: Oct 31, 2020 Completion: Feb 28, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on ALK- Anaplastic Large Cell Lymphoma (ALCL) and Angioimmunoblastic T-cell Lymphoma (AITL), this trial is ongoing. The trial is conducted by Fondazione Italiana Linfomi - ETS and has accumulated 23 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

23 versions recorded

Jan 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jan 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

▶ Show 18 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2022 — Jun 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Mar 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2022 — Mar 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2020 — Dec 2020 [monthly]

Recruiting PHASE1_PHASE2
Oct 2019 — Apr 2020 [monthly]

Recruiting PHASE1_PHASE2
Apr 2019 — Oct 2019 [monthly]

Recruiting PHASE1_PHASE2
Aug 2018 — Apr 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1_PHASE2
Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione Italiana Linfomi - ETS

Data source: Fondazione Italiana Linfomi - ETS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Aviano, Italy , Bologna, Italy , Brescia, Italy , Cagliari, Italy , Cuneo, Italy , Genova, Italy , Meldola, Italy , Milan, Italy , Napoli, Italy and 13 more locations